After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million. The oncology biotech ...
Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...
Eikon Therapeutics, Inc. (EIKN) has filed to raise development capital in an IPO of its common stock, according to SEC S-1 registration information. The company is a large biopharma firm developing ...
Eyes will be on Eikon’s upcoming data readout for its toll-like receptors 7 and 8 (TLR7/8) co-agonist, as the company looks to buck the trend of recent clinical trial failures with candidates that ...
HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results